Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlan Krasner - Chief EndocrinologistCatherine Novack - Director of Healthcare Equity ResearchGayathri Diwakar - Head of Investor RelationsIsabel Kalofonos - Chief Commercial OfficerScott Struthers - Founder and CEOToby Schilke - CFOConference Call ParticipantsAlex Thompson - Senior Equity Research AnalystAndy Chen - Director and Senior Equity Research AnalystDennis Ding - VP and Equity Research ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlan Krasner - Chief EndocrinologistCatherine Novack - Director of Healthcare Equity ResearchGayathri Diwakar - Head of Investor RelationsIsabel Kalofonos - Chief Commercial OfficerScott Struthers - Founder and CEOToby Schilke - CFOConference Call ParticipantsAlex Thompson - Senior Equity Research AnalystAndy Chen - Director and Senior Equity Research AnalystDennis Ding - VP and Equity Research ...

Crinetics Pharmaceuticals (NasdaqGS:CRNX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker14Welcome to Crinetics Pharmaceuticals' fourth quarter and full year 2025 financial results conference call. At this time, all participants are in listen only mode. Following management's prepared remarks, we will hold a question and answer session. In order to ask a question, please press star then 1 on your telephone. I'd now like to turn the call over to Gayathri Diwakar, Head of Investor Relations. Pleas ...

February 26, 2026 Fourth Quarter and Full Year 2025 Financial Results and Business Update Forward Looking Statements This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forward-looking statements include, but are not limited to, statements regarding: our ability to effectively comme ...

PALSONIFY™ (Paltusotine) Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent Cushing's Syndrome to Initiate in the First Half of 2026 Multiple Clinical Trials Initiated for Early- and Late-Stage Candidates Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a gl ...

Core Insights - Crinetics Pharmaceuticals, Inc. will participate in two upcoming investor conferences, providing opportunities for 1x1 meetings with management [1][2] - The company focuses on transforming the treatment of endocrine diseases and related tumors through innovative therapies [3] - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for acromegaly, with additional programs in development for various endocrine conditions [4] Group 1: Upcoming Events - Crinetics will attend the TD Cowen 46 Annual Health Care Conference in Boston on March 4, 2026, with a fireside chat scheduled for 1:50 p.m. Eastern Time [1] - Management will also be available for 1x1 meetings on March 4, 2026, and at the Leerink Annual Global Healthcare Conference in Miami on March 11, 2026 [1] Group 2: Company Overview - Crinetics Pharmaceuticals is dedicated to discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) [3] - The company has a pipeline of over 10 disclosed programs, including late-stage candidates for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome [4] - Additional discovery programs address various endocrine conditions such as Graves' disease, polycystic kidney disease, and GPCR-targeted oncology indications [4]

Core Insights - Crinetics Pharmaceuticals, Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, after market close, followed by a conference call at 4:30 p.m. ET to discuss the results and provide a business update [1]. Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors through patient-centered science [4]. - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [4]. Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [5]. - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [5]. - The company has a deep pipeline of over 10 disclosed programs, including late-stage investigational candidate atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682, a nonpeptide drug conjugate for treating SST2 expressing neuroendocrine tumors and other solid tumors [5]. - Additional discovery programs target various endocrine conditions such as Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [5].

JANUARY 2026 Beyond Innovation to Impact: Building the Premier Endocrinology Business J.P. Morgan Healthcare Conference Angela Living with Acromegaly Forward Looking Statements and Legal Disclaimers Forward Looking Statements: This presentation contains forward-looking statements. Crinetics Pharmaceuticals, Inc. ("Crinetics," the "company," "we," "us," or "our") cautions you that all statements other than statements of historical facts contained in this presentation are forward-looking statements. Such forw ...

Core Viewpoint - Crinetics Pharmaceuticals, Inc. has announced a public offering of 7,620,000 shares at a price of $45.95 per share, aiming to raise approximately $350 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering consists entirely of shares sold by Crinetics, with a 30-day option for underwriters to purchase an additional 1,143,000 shares [1]. - The expected closing date for the offering is around January 8, 2026, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for commercial activities related to the launch of PALSONIFY™, R&D of product candidates, and general corporate purposes, including capital expenditures and working capital [2]. - Crinetics may also consider using a portion of the proceeds for in-licensing, acquiring, or investing in complementary businesses or technologies, although there are no current commitments to do so [2]. Group 3: Company Overview - Crinetics Pharmaceuticals focuses on developing novel therapeutics for endocrine diseases and related tumors, with expertise in targeting G-protein coupled receptors (GPCRs) [6]. - The company's lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the FDA for adults with acromegaly who have not responded adequately to surgery [7]. - Crinetics has a pipeline of over 10 disclosed programs, including candidates for congenital adrenal hyperplasia and neuroendocrine tumors, addressing various endocrine conditions [7].

Core Insights - Crinetics Pharmaceuticals, Inc. is preparing to host a conference call on January 5, 2026, to discuss the commercialization of PALSONIFY, the first FDA-approved oral treatment for acromegaly, and to share results from the Phase 2 trial of atumelnant for congenital adrenal hyperplasia [1][6] Group 1: Company Overview - Crinetics focuses on developing treatments for endocrine diseases, utilizing small molecules that target G-protein coupled receptors (GPCRs) [2] - The company's pipeline includes atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, as well as CRN09682 for SST2 expressing tumors [2] Group 2: Financial Performance - Evercore ISI has maintained an "Outperform" rating for CRNX, raising the price target from $80 to $90, despite the stock price being $52.57 and a negative price-to-earnings (P/E) ratio of -10.29 [3] - The company has a high price-to-sales ratio of 2,856.31 and an elevated enterprise value to sales ratio of 2,816.08, indicating that investors are paying a premium for its sales [4] - Crinetics has a negative earnings yield of -9.72%, but maintains a low debt-to-equity ratio of 0.046, reflecting minimal reliance on debt [5] - The company exhibits a strong liquidity position with a current ratio of 15.12, indicating it can comfortably cover its short-term liabilities [5]